Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fast-acting insulin aspart vs NovoRapid in T2D (Onset 9)
NCT03268005Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2017
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Glycosylated Haemoglobin at 16 weeks. Started Sep 2017; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03268005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03268005.